Myeloma, or multiple myeloma, is a cancer affecting a particular type of blood cells, called plasma cells. Myeloma is most common in people over 60 and is characterized by the accumulation of ...

Despite being the second most common haematologic cancer globally, treatment options for multiple myeloma remain limited, with a significant need for new therapies. 1 Multiple myeloma originates i ...

Multiple myeloma, the second most common haematological malignancy worldwide after non-Hodgkin lymphoma, is characterized by the abnormal proliferation of plasma cells in the bone marrow.

Early treatment with intravenous bisphosphonates at first radiographic evidence of bone lesions in patients with solid tumors or evidence of osteopenia in patients with multiple myeloma can ...

The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for ...

Inc. today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Bristol Myers Squibb (BMS). "We are pleased to see Abecma expansion in the third ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

A breakthrough CAR-T cell therapy, Qartemi, has been approved for blood cancer patients in India, offering new hope to those ...

Genmab A/S (NASDAQ:GMAB – Get Free Report) is projected to announce its earnings results on Wednesday, February 12th. Analysts expect the company to announce earnings of $0.28 per share and revenue of ...

China Universal Asset Management Co. Ltd. purchased a new position in 2seventy bio, Inc. (NASDAQ:TSVT – Free Report) during the fourth quarter, HoldingsChannel reports. The fund purchased 10,939 ...